Pfizer Inc. $PFE Shares Purchased by U.S. Capital Wealth Advisors LLC

Key Points

• U.S. Capital Wealth Advisors LLC increased its stake in Pfizer Inc. by 15.5%, acquiring an additional 61,977 shares, bringing their total holdings to 461,949 shares valued at $11.2 million.
• Despite a slight decrease of 0.5% in share price, Pfizer reported a strong quarterly earnings performance, with an EPS of $0.78, surpassing expectations and showcasing a year-over-year revenue growth of 10.3%.
• Wall Street analysts have mixed opinions on Pfizer, with a consensus rating of "Hold" and a target price of $28.12, reflecting caution amidst varying price targets from different firms.

U.S. Capital Wealth Advisors LLC grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 15.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 461,949 shares of the biopharmaceutical company's stock after purchasing an additional 61,977 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Pfizer were worth $11,198,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares during the period. Vident Advisory LLC bought a new stake in Pfizer during the fourth quarter valued at approximately $248,000. GTS Securities LLC raised its stake in shares of Pfizer by 127.1% during the fourth quarter. GTS Securities LLC now owns 44,452 shares of the biopharmaceutical company's stock worth $1,179,000 after acquiring an additional 208,555 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Pfizer in the fourth quarter worth $3,708,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock traded up $0.02 during midday trading on Monday, hitting $24.05. The company had a trading volume of 67,725,099 shares, compared to its average volume of 42,502,152. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The stock has a market cap of $136.74 billion, a price-to-earnings ratio of 12.79, a PEG ratio of 0.78 and a beta of 0.55. The company's 50 day simple moving average is $24.61 and its 200 day simple moving average is $24.18.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Bank of America boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.